347850.KQ
D&D Pharmatech
KOE · Healthcare · Biotechnology · KR
KRW 48,500.00
−1.12%Year over year
Reported trailing growth
- Revenue
- -70.5%
- EBITDA
- -42.8%
- EBIT
- -20.5%
- EPS
- +42.6%
- Free cash flow
- +7.4%
- Operating cash flow
- +6.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +91.6%
- EBITDA
- -17.5%
- EBIT
- -35.9%
- Net income
- +17.7%
- EPS
- +22.5%
- Free cash flow
- +4.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026